DaynaIsaacsMDMPH(She/Her)

PubMed

• A Case of Posterior Reversible Encephalopathy Syndrome Associated With Pembrolizumab and Cetuximab Combination Therapy.
  Neeja Patel, Rohan Karanth, Dayna J Isaacs, Joss Cohen, Deborah J Wong
  Cureus. 2024-10-01
• Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy.
  Dayna Jill Isaacs, Nikhita Kathuria-Prakash, Robin Hilder, Melissa G Lechner, Alexandra Drakaki
  Current Cancer Reports. 2024-02-20
• 2 citations
  Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
  Gavin Hui, Dimitrios Stefanoudakis, Yuliya Zektser, Dayna Jill Isaacs, Christopher Hannigan
  Current Oncology. 2023-08-04

Journal Articles

• Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy  
  Dayna Jill Isaacs, Nikhita Kathuria-Prakash, Robin Hilder, Melissa G. Lechner, Alexandra Drakaki, Current Cancer Reports, 1/29/2024
• Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with pre-existing type 1 diabetes mellitus  
  • Hilder R, Tsai K, Quandt Z, Isaacs DJ, Drakaki D, Xing Y, In GK, Angell TE, Lechner MG, Frontiers in Endocrinology, 10/11/2023

Abstracts/Posters

• Are severe immune-related adverse events more likely in patients with preexisting autoimmune disease?
  Isaacs DJ, Hilder R, Drakaki D, Lechner MG, Journal of Clinical Oncology, 2023